Needham Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $73
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia maintains a 'Buy' rating on Intra-Cellular Therapies (NASDAQ:ITCI) and raises the price target from $70 to $73.
July 06, 2023 | 11:43 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst maintains a 'Buy' rating on Intra-Cellular Therapies and raises the price target from $70 to $73.
The news of Needham maintaining a 'Buy' rating and raising the price target for Intra-Cellular Therapies is directly related to the company and is likely to have a positive impact on its stock price in the short term. Investors may see this as a sign of confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100